2022 年第 5 期 第 17 卷

卡瑞利珠单抗联合同期放化疗治疗晚期宫颈癌患者的临床效果

Clinical effect of camrelizumab combined with concurrent chemoradiotherapy on patients with advanced cervical cancer

作者：闫沛王彩锋王治海

英文作者：Yan Pei Wang Caifeng Wang Zhihai

单位：山西省肿瘤医院药学部，太原030001

英文单位：Department of Pharmacy Shanxi Provincial Cancer Hospital Taiyuan 030001 China

关键词：宫颈癌；卡瑞利珠单抗；程序性死亡受体1；程序性死亡受体配体1；免疫治疗

英文关键词：Cervicalcancer;Camrelizumab;Programmeddeath-1;Programmeddeathligand-1;Immunotherapy

• 摘要：

• 目的 观察卡瑞利珠单抗联合同期放化疗治疗晚期宫颈癌患者的临床效果。方法 收集2020年6月1日至2021年8月31日在山西省肿瘤医院接受治疗的121例晚期宫颈鳞状细胞癌患者的临床资料行回顾性分析。依据治疗方案将患者分为观察组(57例)和对照组(64例)，观察组接受同期放化疗并联合卡瑞利珠单抗进行免疫治疗，对照组只接受同期放化疗。比较2组病例的基线资料、治疗效果、血清肿瘤标志物水平、免疫功能水平和不良反应。结果 观察组与对照组年龄、体重指数、Karnofsky评分、原发病灶直径差异均无统计学意义（均P>0.05）。观察组总有效率高于对照组［52.6%（30/57）比28.1%（18/64）］，差异有统计学意义（χ2=7.566，P=0.006）。2组治疗后癌胚抗原、糖类抗原19-9、鳞状上皮细胞癌相关抗原、细胞角蛋白19片段水平差异均无统计学意义（均P>0.05）。治疗后观察组CD+3、CD+4、CD+8水平均高于对照组，差异均有统计学意义（均P<0.05）。观察组与对照组均未发生Ⅲ级以上不良反应，观察组骨髓抑制、肝肾功能异常、恶心、发热的发生率低于对照组，差异均有统计学意义（均P<0.05），其余不良反应差异均无统计学意义（均P>0.05）。结论  卡瑞利珠单抗联合同期放化疗能够提高晚期宫颈癌症患者在一定时期内的总有效率，改善其免疫功能。

• Objective  To observe the clinical effect of camrelizumab combined with concurrent chemoradiotherapy on patients with advanced cervical cancer. Methods The clinical data of 121 patients with advanced cervical squamous cell carcinoma admitted to Shanxi Provincial Cancer Hospital from June 1, 2020 to August 31, 2021 were collected and analyzed retrospectively. According to the treatment, the patients were divided into observation group (57 cases) and control group (64 cases). The observation group received concurrent chemoradiotherapy combined with camrelizumab for immunotherapy, and the control group only received concurrent chemoradiotherapy. The baseline data, curative effect, level of serum tumor marker, level of immune function and adverse reactions of the two groups were compared. Results  There were no significant differences in age, body mass index, Karnofsky score and primary lesion diameter between the observation group and the control group (all P>0.05). The total effective rate of the observation group was higher than that of the control group ［52.6%(30/57) vs 28.1%(18/64)］, and the difference was statistically significant(χ2=7.566, P=0.006）. There were no significant differences in the levels of carcinoembryonic antigen, carbohydrate antigen 19-9, squamous cell carcinoma associated antigen and cytokeratin 19 fragment between the two groups after treatment(all P>0.05). After treatment, the levels of CD+3, CD+4 and CD+8 of the observation group were significantly higher than those of the control group(all P<0.05). There were no adverse reactions above grade Ⅲ in the observation group and the control group. The incidences of bone marrow suppression, abnormal liver and kidney function, nausea and fever of the observation group were lower than those of the control group (all P<0.05), and there was no significant difference in other adverse reactions(all P>0.05). Conclusion The total effective rate and immune function of patients with advanced cervical cancer who received camrelizumab combined with concurrent chemoradiotherapy were significantly improved in a period.